Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: coronavirus hybrid vaccines - NuGenerex Immuno-Oncology

Drug Profile

Research programme: coronavirus hybrid vaccines - NuGenerex Immuno-Oncology

Alternative Names: 2019-nCOV hybrid vaccines - NuGenerex Immuno-Oncology; 2019-nCOV specific Li-Key-hybrids vaccines

Latest Information Update: 17 Feb 2020

At a glance

  • Originator NuGenerex Immuno-Oncology
  • Class Peptide vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action CD4-positive T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 06 Feb 2020 Coronavirus hybrid vaccines - NuGenerex Immuno-Oncology is available for licensing as of 06 Feb 2020. www.generex.com
  • 06 Feb 2020 Early research in COVID-2019-infections (Prevention) in USA (Parenteral)

Development Overview

Introduction

Hybrid vaccines based on the Li-Key peptide vaccine technology are being developed by NuGenerex Immuno-Oncology (previously Antigen Express and wholly-owned subsidiary of Generex) for the prevention of COVID-2019 infections. The proprietary technology utilises the 4-amino acid Li-Key peptide which is chemically linked to synthetic peptides that mimic as essential epitope of the virus. The Li-Key peptide by interacting with the allosteric site of MHC Class II molecules causes displacement of the existing antigens and anchors the chemically linked viral epitope to the antigen binding domain. This interaction allows the hybrid vaccine to bypass all requirements for antigen processing and results in enhanced activation of CD4+ T cells and improves long-term immunologic memory. The hybrid vaccine is composed of naturally occurring amino acids which helps in prevention of adverse reactions. Early stage development is ongoing in the US.

NuGenerex Immuno-Oncology is seeking partners for the development of hybrid vaccines for prevention of COVID-2019 infections [1] .

Patent Information

The use of Antigen Express's Li-Key technology in the development of immunotherapeutic vaccines is covered by a granted patent in Japan, international counterparts in the US, Europe, Australia, and China, and a pending application in Canada [2] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Peptide vaccines, Synthetic vaccines, Viral vaccines
  • Target CD4-positive T lymphocyte
  • Mechanism of Action CD4-positive T lymphocyte stimulants; Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7E9 (All other viral vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research USA Parenteral / unspecified NuGenerex Immuno-Oncology 06 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
NuGenerex Immuno-Oncology Originator USA
NuGenerex Immuno-Oncology Owner USA

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
NuGenerex Immuno-Oncology COVID 2019 infections Unspecified - 06 Feb 2020

Development History

Event Date Update Type Comment
06 Feb 2020 Licensing Status Coronavirus hybrid vaccines - NuGenerex Immuno-Oncology is available for licensing as of 06 Feb 2020. www.generex.com [1] Updated 17 Feb 2020
06 Feb 2020 Phase Change Early research in COVID-2019-infections (Prevention) in USA (Parenteral) [1] Updated 17 Feb 2020
01 Feb 2012 Patent Information NuGenerex Immuno-Oncology has patent pending for Li-Key technology in Canada [2] Updated 17 Feb 2020
01 Feb 2012 Patent Information NuGenerex Immuno-Oncology has patent protection for Li-Key technology in USA, Europe, Australia, China [2] Updated 17 Feb 2020

References

  1. Generex Biotechnology Subsidiaries NuGenerex Immuno-Oncology and NuGenerex Diagnostics Working to Address the Coronavirus Pandemic and Emerging Risk of Avian Flu Using Ii-Key Peptide Vaccines.

    Media Release
  2. Generex Announces Patent Award for its Core Vaccine Technologies in Japan.

    Media Release
Back to top